AI DRUG DEVELOPMENT FACES REALITY CHECK

Major pharmaceutical firms are allocating significant resources to artificial intelligence for drug development, betting the technology can accelerate discovery and reduce costs. AI systems can theoretically screen millions of molecular combinations faster than traditional methods, identifying promising candidates for further testing. However, moving from computational predictions to approved medications remains a steep challenge. The gap between AI identifying potential compounds and those drugs successfully completing clinical trials persists. Early AI-discovered drugs are only now entering later-stage testing phases, meaning years may pass before the technology's actual effectiveness becomes clear. Industry leaders acknowledge both potential and limitations. Success depends on whether AI predictions translate to safe, effective treatments—not merely faster initial screening. The pharmaceutical sector is treating AI as a tool to enhance traditional research rather than replace it entirely, suggesting measured expectations rather than transformative breakthroughs in the near term.